Fayez Sarofim & Co’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $911K | Buy |
10,071
+34
| +0.3% | +$2.85K | ﹤0.01% | 189 |
|
|
2026
Q1 | $804K | Hold |
10,037
| – | – | ﹤0.01% | 191 |
|
|
2025
Q4 | $856K | Sell |
10,037
-440
| -4% | -$36.1K | ﹤0.01% | 190 |
|
|
2025
Q3 | $815K | Hold |
10,477
| – | – | ﹤0.01% | 202 |
|
|
2025
Q2 | $819K | Hold |
10,477
| – | – | ﹤0.01% | 200 |
|
|
2025
Q1 | $759K | Sell |
10,477
-3,278
| -24% | -$235K | ﹤0.01% | 205 |
|
|
2024
Q4 | $1.02M | Sell |
13,755
-210
| -2% | -$14.7K | ﹤0.01% | 185 |
|
|
2024
Q3 | $922K | Hold |
13,965
| – | – | ﹤0.01% | 179 |
|
|
2024
Q2 | $1.29M | Hold |
13,965
| – | – | ﹤0.01% | 159 |
|
|
2024
Q1 | $1.33M | Hold |
13,965
| – | – | ﹤0.01% | 156 |
|
|
2023
Q4 | $1.19M | Sell |
13,965
-1,598
| -10% | -$111K | ﹤0.01% | 156 |
|
|
2023
Q3 | $1.08M | Sell |
15,563
-2,500
| -14% | -$201K | ﹤0.01% | 165 |
|
|
2023
Q2 | $1.7M | Sell |
18,063
-705
| -4% | -$61.3K | 0.01% | 149 |
|
|
2023
Q1 | $1.55M | Sell |
18,768
-105
| -0.6% | -$8.25K | 0.01% | 159 |
|
|
2022
Q4 | $1.41M | Hold |
18,873
| – | – | 0.01% | 155 |
|
|
2022
Q3 | $1.56M | Hold |
18,873
| – | – | 0.01% | 154 |
|
|
2022
Q2 | $1.79M | Sell |
18,873
-460
| -2% | -$47.6K | 0.01% | 150 |
|
|
2022
Q1 | $2.28M | Hold |
19,333
| – | – | 0.01% | 150 |
|
|
2021
Q4 | $2.5M | Sell |
19,333
-643
| -3% | -$75K | 0.01% | 152 |
|
|
2021
Q3 | $2.26M | Hold |
19,976
| – | – | 0.01% | 148 |
|
|
2021
Q2 | $2.07M | Sell |
19,976
-3,560
| -15% | -$336K | 0.01% | 157 |
|
|
2021
Q1 | $1.97M | Buy |
23,536
+3,430
| +17% | +$290K | 0.01% | 143 |
|
|
2020
Q4 | $1.83M | Hold |
20,106
| – | – | 0.01% | 144 |
|
|
2020
Q3 | $1.6M | Buy |
20,106
+422
| +2% | +$32.9K | 0.01% | 143 |
|
|
2020
Q2 | $1.36M | Buy |
19,684
+2,578
| +15% | +$183K | 0.01% | 145 |
|
|
2020
Q1 | $1.08M | Hold |
17,106
| – | – | 0.01% | 145 |
|
|
2019
Q4 | $1.33M | Buy |
17,106
+3,729
| +28% | +$291K | 0.01% | 152 |
|
|
2019
Q3 | $981K | Buy |
13,377
+3,627
| +37% | +$255K | 0.01% | 163 |
|
|
2019
Q2 | $600K | Buy |
9,750
+570
| +6% | +$34.5K | ﹤0.01% | 179 |
|
|
2019
Q1 | $585K | Buy |
9,180
+420
| +5% | +$24K | ﹤0.01% | 177 |
|
|
2018
Q4 | $447K | Sell |
8,760
-420
| -5% | -$21.3K | ﹤0.01% | 185 |
|
|
2018
Q3 | $533K | Hold |
9,180
| – | – | ﹤0.01% | 182 |
|
|
2018
Q2 | $445K | Buy |
+9,180
| New | +$428K | ﹤0.01% | 191 |
|
Other funds holding EW
Fayez Sarofim & Co's EW Position: Q2 2026 in Review
Fayez Sarofim & Co increased its Edwards Lifesciences (EW) stake by 0.34% in Q2 2026, buying an estimated $2.85K and bringing the position to 10,071 shares worth $911K. The position accounts for ﹤0.01% of the portfolio, ranked #189.
Fayez Sarofim & Co first reported a position in EW in Q2 2018 and has held it in 33 quarters since. The position peaked at $2.5M in Q4 2021. 1,327 funds tracked by Wall St. Rank hold EW as of Q2 2026.
- Fayez Sarofim & Co held 10,071 shares of Edwards Lifesciences worth $911K as of Q2 2026.
- Fayez Sarofim & Co bought 34 Edwards Lifesciences shares in Q2 2026, an estimated $2.85K.
- Edwards Lifesciences made up ﹤0.01% of Fayez Sarofim & Co's portfolio in Q2 2026, its #189 holding.
- Fayez Sarofim & Co first reported a position in Edwards Lifesciences in Q2 2018 and has held it in 33 quarters since.
- Fayez Sarofim & Co's Edwards Lifesciences position peaked at $2.5M in Q4 2021.
- 1,327 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.
Based on Fayez Sarofim & Co's 13F filing for Q2 2026, filed 17 Aug 2026.